Skip to main content

Investor Relations Contact Us Careers

About Femasys
- Our Mission
- Leadership
Healthcare Providers
- Fertility Portfolio
- Permanent Birth Control
Patients
Media
- All
- News
- Videos
- Webinars
- Podcasts
- Blog
- Media Kits
Investor Relations Contact Us Careers

News Item

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

March 10, 2026

View source →

← Back to Media

A biomedical innovator redefining women’s reproductive health at a global scale through transformative innovations.

Who We Are
Leadership
Investor Relations

Fertility
Permanent Birth Control

Careers
Contact Us

FemaSeed.com →
FemVue.com →
FemBloc.com →
FemCerv.com →

© 2026 Femasys Inc. FemaSeed^®, FemSperm™, FemVue^®, SpermVue™, FemBloc^®, FemCerv^® are registered trademarks of Femasys Inc. All rights reserved. Privacy Policy Terms of Use Accessibility Patents Ordering

We use cookies to understand site traffic and improve your experience. See our Privacy Policy for details.